0001209191-24-000812.txt : 20240104
0001209191-24-000812.hdr.sgml : 20240104
20240104164351
ACCESSION NUMBER: 0001209191-24-000812
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wilson Marc
CENTRAL INDEX KEY: 0001702265
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 24512739
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001702265
Wilson Marc
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
0
1
0
0
CFO
1
Common Stock
2024-01-02
4
M
0
10000
9.28
A
106055
D
Common Stock
2024-01-02
4
S
0
10000
35.47
D
96055
D
Non-qualified stock option (Right to Buy)
9.28
2024-01-02
4
M
0
10000
0.00
D
2028-05-24
Common Stock
10000
51185
D
Includes 454 shares acquired under the Issuer's Employee Stock Purchase.
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.47 per share. The range of sales prices on the transaction date was $34.41 to $36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Marc Wilson
2024-01-04